Insider Selling: Roivant Sciences (NASDAQ:ROIV) Insider Sells 1,400,000 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Frank Torti sold 1,400,000 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $27.42, for a total transaction of $38,388,000.00. Following the sale, the insider owned 13,736,547 shares in the company, valued at approximately $376,656,118.74. The trade was a 9.25% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Frank Torti also recently made the following trade(s):

• On Friday, February 20th, Frank Torti sold 1,012,610 shares of Roivant Sciences stock. The stock was sold at an average price of $27.15, for a total value of $27,492,361.50.
• On Monday, February 23rd, Frank Torti sold 587,390 shares of Roivant Sciences stock. The stock was sold at an average price of $27.51, for a total transaction of $16,159,098.90.

Roivant Sciences Stock Performance

Shares of ROIV stock traded up $0.61 on Monday, reaching $27.76. The stock had a trading volume of 4,414,766 shares, compared to its average volume of 6,823,292. The company has a 50 day simple moving average of $23.44 and a 200 day simple moving average of $19.07. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $27.94.

Analyst Upgrades and Downgrades

ROIV has been the subject of a number of analyst reports. Guggenheim increased their price objective on shares of Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Leerink Partners increased their price target on Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. TD Cowen restated a “buy” rating on shares of Roivant Sciences in a report on Saturday, February 7th. The Goldman Sachs Group increased their target price on Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Finally, Weiss Ratings downgraded Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, February 9th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Roivant Sciences has an average rating of “Moderate Buy” and an average price target of $28.69.

Institutional Trading of Roivant Sciences

Institutional investors have recently modified their holdings of the company. UBS Group AG increased its position in shares of Roivant Sciences by 570.0% in the fourth quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after buying an additional 15,645,836 shares in the last quarter. Morgan Stanley increased its stake in shares of Roivant Sciences by 31.7% during the fourth quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock worth $1,266,402,000 after purchasing an additional 14,036,696 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Roivant Sciences by 365.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock worth $238,323,000 after purchasing an additional 8,621,567 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in Roivant Sciences by 11,507.5% in the 4th quarter. Assenagon Asset Management S.A. now owns 6,937,112 shares of the company’s stock valued at $150,535,000 after buying an additional 6,877,348 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Roivant Sciences in the fourth quarter valued at approximately $112,750,000. 64.76% of the stock is currently owned by institutional investors.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.